



Response of Npt2a knockout mice to dietary calcium and phosphorus

Citation

Li, Yuwen, Daniel Caballero, Julian Ponsetto, Alyssa Chen, Chuanlong Zhu, Jun Guo, Marie Demay, Harald Jüppner, and Clemens Bergwitz. 2017. "Response of Npt2a knockout mice to dietary calcium and phosphorus." PLoS ONE 12 (4): e0176232. doi:10.1371/journal.pone.0176232. <http://dx.doi.org/10.1371/journal.pone.0176232>.

Published Version

doi:10.1371/journal.pone.0176232

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:33029850>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

RESEARCH ARTICLE

Response of *Npt2a* knockout mice to dietary calcium and phosphorus

Yuwen Li^{1,2}, Daniel Caballero³, Julian Ponsetto³, Alyssa Chen³, Chuanlong Zhu^{4,5}, Jun Guo¹, Marie Demay¹, Harald Jüppner^{1,6}, Clemens Bergwitz^{3*}

1 Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, **2** Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China, **3** Section Endocrinology, Yale University School of Medicine, New Haven, Connecticut, United States of America, **4** Gastroenterology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, **5** Department of Infectious Diseases, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China, **6** Pediatric Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

☞ These authors contributed equally to this work.

* clemens.bergwitz@yale.edu



OPEN ACCESS

Citation: Li Y, Caballero D, Ponsetto J, Chen A, Zhu C, Guo J, et al. (2017) Response of *Npt2a* knockout mice to dietary calcium and phosphorus. PLoS ONE 12(4): e0176232. <https://doi.org/10.1371/journal.pone.0176232>

Editor: Tatsuo Shimomura, The University of Tokyo, JAPAN

Received: February 15, 2017

Accepted: April 8, 2017

Published: April 27, 2017

Copyright: © 2017 Li et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by National Institutes of Health Grants R01-DK46718-20 and P01-DK11794, project IV (to HJ), National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Grant 5K08-DK078361 (to CB), Center for Skeletal Research Core NIH P30 AR066261 (to MD), Young Investigator Awards by the National Kidney Foundation, and the American Society for Clinical

Abstract

Mutations in the renal sodium-dependent phosphate co-transporters *NPT2a* and *NPT2c* have been reported in patients with renal stone disease and nephrocalcinosis, but the relative contribution of genotype, dietary calcium and phosphate to the formation of renal mineral deposits is unclear. We previously reported that renal calcium phosphate deposits persist and/or reappear in older *Npt2a*^{-/-} mice supplemented with phosphate despite resolution of hypercalciuria while no deposits are seen in wild-type (WT) mice on the same diet. Addition of calcium to their diets further increased calcium phosphate deposits in *Npt2a*^{-/-}, but not WT mice. The response of PTH to dietary phosphate of *Npt2a*^{-/-} was blunted when compared to WT mice and the response of the urinary calcium x phosphorus product to the addition of calcium and phosphate to the diet of *Npt2a*^{-/-} was increased. These findings suggest that *Npt2a*^{-/-} mice respond differently to dietary phosphate when compared to WT mice. Further evaluation in the *Npt2a*^{-/-} cohort on different diets suggests that urinary calcium excretion, plasma phosphate and FGF23 levels appear to be positively correlated to renal mineral deposit formation while urine phosphate levels and the urine anion gap, an indirect measure of ammonia excretion, appear to be inversely correlated. Our observations in *Npt2a*^{-/-} mice, if confirmed in humans, may be relevant for the optimization of existing and the development of novel therapies to prevent nephrolithiasis and nephrocalcinosis in human carriers of *NPT2a* and *NPT2c* mutations.

Introduction

Mutations in the sodium phosphate co-transporters, *NPT2a* [1–3] and *NPT2c* [4, 5] cause hypophosphatemic rickets with hypercalciuria (HHRH) and idiopathic hypercalciuria (IH). Affected individuals show renal phosphate-wasting, high circulating levels of 1,25(OH)₂D and

Investigation (to CB), National Natural Science Foundation of China grant 81271713 (to CZ) and the Scientific research fund of Anhui Medical University 2011xkj074 (to YL). We are grateful to the Yale Mouse Metabolic Phenotyping Center NIH U24 DK-059635 and the Yale O'Brien Center Renal Physiology Core NIH P30DK079310 for help with biochemical analysis, the Yale Dept. of Orthopaedics Histology and Histomorphometry Laboratory for help with histological and the Yale Center for Cellular and Molecular Imaging (YCCMI) for electron microscopic analysis and the Yale School of Medicine Dept. Biostatistics for help with statistical analysis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

absorptive hypercalciuria. As a result they develop intraluminal stones (nephrolithiasis) and mineral deposits in the renal parenchyma (nephrocalcinosis) [4–7]. Furthermore, *NPT2a* has also been associated with nephrolithiasis [8] and altered renal function [9–11] in genome-wide association studies. Although little is known about the prevalence in stone patients, one compound heterozygous *NPT2a* mutations and one compound heterozygous carrier of *NPT2c* mutations was identified in a small cohort comprised of 272 genetically unresolved individuals (106 children and 166 adults) from 268 families with nephrolithiasis ($n = 256$) or isolated nephrocalcinosis ($n = 16$) [12]. Oral phosphate supplements are currently thought to reduce the risk for renal mineralization in carriers of *NPT2a* and *NPT2c* mutations by lowering circulating levels of 1,25(OH)₂D and absorptive hypercalciuria. However, there is concern that, despite a reduction in urine calcium excretion, this therapy could contribute to the formation of renal calcium phosphate deposits under certain conditions.

This concern is based on several observations: i) renal calcium-phosphate deposits are found in the nephrocalcinosis that can develop in patients with X-linked hypophosphatemia (XLH) treated with oral phosphate supplements given multiple times throughout the day [13, 14] and in otherwise healthy individuals following treatment with phosphate enema [15] despite the absence of hypercalciuria; ii) in a recent survey of 27 kindreds with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) we reported that a 10% decrease in tubular reabsorption of phosphate (TRP) predicts a two-fold increase in renal mineralization, independent of *NPT2c* mutation carrier status [16]; iii) dietary phosphate may increase the saturation product of calcium and phosphate by increasing urinary phosphate, which appears to be an important predictor of renal mineralization [17, 18]; iv) alterations in the levels of extracellular matrix factors affecting binding of phosphate to hydroxyapatite crystals such as *osteopontin* (*Opn*) or genes involved in the synthesis of pyrophosphate (PPi) and phosphate in the interstitial matrix such as *Extracellular nucleotide pyrophosphatase phosphodiesterase 1* (*Enpp1*) are associated with renal mineralization [19, 20]. v) We recently reported that *Npt2a*^{-/-} mice show reduced urine osteopontin excretion when compared to WT mice and *Npt2a*^{-/-};*Opn*^{-/-} mice show an increased size of mineral deposits in their kidneys [21].

In the present study we compared the degree of renal mineralization of WT and *Npt2a*^{-/-} mice on diets with varying calcium and phosphate contents with the serum and urine biochemistries in response to these diets. Our findings suggest that *Npt2a*^{-/-} mice respond differently to dietary phosphate when compared to WT mice and that within the *Npt2a*^{-/-} cohort the degree of renal mineralization positively correlates with plasma phosphate and FGF23, and urinary calcium excretion, while it inversely correlates with urine phosphate and anion gap as a measure of proximal tubular bicarbonate and distal tubular ammonia excretion. Our observations in *Npt2a*^{-/-} mice, if confirmed in humans, may be relevant for the optimization of existing and the development of novel therapies to prevent nephrolithiasis and nephrocalcinosis in carriers of *NPT2a* and *NPT2c* mutations.

Materials and methods

Animals

Mice were euthanized in deep anesthesia with isoflurane by removal of vital organs. The research under IACUC protocol 2014–11635 was first approved Oct. 22 2014 by the Yale Institutional Animal Care and Use Committee (IACUC), renewed Sept. 7 2016, valid through Sept. 30 2017. Yale University has an approved Animal Welfare Assurance (#A3230-01) on file with the NIH Office of Laboratory Animal Welfare. The Assurance was approved May 5, 2015.

Male and female C57BL/6 mice were obtained from Charles River Laboratory, MA. Male and female *Npt2a*^{-/-} mice (B6.129S2-*Slc34a1*^{tm1Hten}/J, Stock No: 004802), were purchased from

The Jackson Laboratory (Bangor, ME). *Npt2c*^{-/-} mice were kindly provided by Dr. Hiroko Segawa, Dept. of Molecular Nutrition Institution of Health Bioscience, The Univ. of Tokushima Graduate School, Tokushima, Japan [22]. Mice were genotyped by PCR amplification of genomic DNA extracted from tail clippings and amplified by polymerase chain reaction (PCR) as described [22–25]. Mice were weaned at 3 weeks of age and allowed free access to water and normal chow (1.0% calcium, 0.7% phosphate, of which 0.3% is readily available for absorption, Harlan Teklad TD.2018S). At 8 weeks of age they were randomized to special diets using egg whites as protein source for 10 to 30 weeks: Normal phosphate, high calcium high vitamin D (TD.110762) contained 0.3% Pi, 2% Ca and 4.5 IU cholecalciferol (vitamin D₃), phosphate deficient, high calcium, high vitamin D₃ (TD.110761) contained 0.02% Pi, 2% Ca, 4.5 IU vitamin D₃, HPC (high phosphate and high calcium) diet (TD.96348) contained 20% Lactose, 2.0% Ca, 1.25% Pi; HP (high phosphate) diet (TD.85349) contained 0.6% Ca, 1.2% Pi and CO (control diet) diet (TD.09803) contained 0.6%Ca, 0.3% Pi (S1 Fig). In all diets caloric content was 3.7 kcal/g, vitamin D₃ content was 2 IU/g, the magnesium content was 0.2%. *Npt2a*^{-/-} mice can be maintained as homozygous line since they are viable and fertile. These mice were out-bred against C57Bl6 wild-type mice and heterozygous mice were mated to obtain *Npt2a*^{-/-} and WT littermates to serve as controls with similar genetic background in our study. Since no differences were observed between genders data from males and females were pooled for the current study.

Blood and urine parameters

Biochemical analyses were done on blood samples collected after cardiac puncture or orbital exsanguination following an overnight fast in deep anesthesia with isoflurane, immediately before animals were euthanized by removal of vital organs. Concentrations of serum and urinary total calcium (Ca), serum and urine inorganic phosphorus (S-P), urine sodium (U-Na), potassium (U-K), chloride (U-Cl) and blood urea nitrogen (S-BUN) were determined using Stanbio Laboratories (Boerne, Texas) kits #0155, #0830, #0140, #0160, #0210 and #0580, respectively. The concentration of urine creatinine (U-crea) and of serum 1,25-dihydroxyvitamin D (1,25(OH)₂D) were determined using R&D systems (Minneapolis, MN) kit #KGE005 and #AC-62F1, respectively. Urine oxalate (U-oxalate) was determined using ABCAM kit #196990. Urine citrate was measured with the Roche Citric Acid UV-Method # 10139076035. Concentrations of plasma intact parathyroid hormone (PTH) and c-terminal fibroblast growth factor 23 (FGF23) were determined using Immutopics (San Clemente, CA) kit #60–2305 and #60–6300, respectively. c-terminal FGF23 ELISAs measure total FGF23 that includes intact FGF23 and its fragments. Unless altered processing of FGF23 is suspected total FGF23 ELISAs correlate well with the intact FGF23 ELISAs [26]. Internal standards were used to assure reproducibility between batches. The urine anion gap was calculated using the formula urine Na (mmol/l) + urine K (mmol/l) – urine Cl (mmol/l). SI correction factors are for Ca (mg/dl)* 0.25 = Ca (mmol/L), P (mg/dl)*0.32 = P (mmol/L), creatinine (mg/dl)* 88.4 = creatinine (umol/L). Fractional excretion indexes were calculated using the formula PEI = urine Pi/(urine creatinine*plasma Pi) or CEI = urine Ca/(urine creatinine*serum Ca), respectively.

Inulin clearance

Inulin clearance was determined using serial tail bleedings following tail-vein injection of FITC-inulin as previously described [27]. Briefly, FITC-inulin (Sigma, St. Louis, MO) was dialyzed (molecular weight cutoff = 1,000) against 150 mM NaCl. 7.48μl/g body weight was injected via the tail vein. Tail vein blood was then collected at 5, 10, 20, 30, 40, 50, 60, 75, 90 and 120 min post injection of FITC-inulin and the plasma was assessed for FITC fluorescence

(λ excitation = 485 nm; λ emission = 535 nm) using a Victor3 plate reader (PerkinElmer, Waltham, MA). Mice tolerated serial tail bleeds well permitting us to measure the same mice after 10, 20 and 30 weeks on HPC diet. GFR was calculated by fitting the data to a biexponential decay function and using the equation $GFR = I/(A/\alpha + B/\beta)$, where I is the amount of FITC-inulin delivered by the bolus injection, A and B are the y-intercepts of the two decay components, and α and β are the corresponding decay constants for the distribution and elimination phases, respectively [28].

Kidney histology

Left kidneys were fixed in 4% formalin/PBS at 4°C for 12 h and then dehydrated with increasing concentration of ethanol and xylene, followed by paraffin embedding. Mineral deposits were determined on 10 μ m von Kossa stained sections counterstained with 1% methyl green. Hematoxyline/eosin was used as counterstain for morphological evaluation. Histomorphometric evaluation was performed using an Osteomeasure System (Osteometrics, Atlanta, GA). % calcified area was determined using the formula: calc. area = 100* calcified area/total area, and mineralization size was determined using the formula: calc. size = calcified area/number of mineralization.

For transmission electron microscopy a 1 mm³ block of the left kidney was fixed in 2.5% Glutaraldehyde and 2% paraformaldehyde in phosphate buffered saline for 2 hrs., followed by post-fixation in 1% osmium liquid for 2 hours. Dehydration was carried out using a series of ethanol concentrations (50% to 100%). Renal tissue was embedded in epoxy resin, and polymerization was carried out at 60°C for overnight. After preparing a thin section (50 nm), the tissues were double stained with uranium and lead and observed using a Tecnai Biotwin (LaB6, 80 kV) (FEI, Thermo Fisher, Hillsboro, OR) at the Yale Center for Cellular and Molecular Imaging (YCCMI).

Statistical analysis

Data are expressed as means \pm SEM and were analyzed in Prism 7.0 (GraphPad Software, Inc., La Jolla, CA) and JMP Pro 11 (SAS, Cary, NC). Differences between groups were considered significant, if p-values obtained with linear regression analysis, or with two-way ANOVA were smaller than 0.05. Tukey's test for multiple comparisons was used where indicated.

Results

Npt2a^{-/-} mice form renal mineral deposits on HP diet

Humans with loss-of-function of *NPT2a* [1–3] and *NPT2c* [4, 5] develop renal mineralization, which may manifest during early childhood prior to specific therapy or when inappropriately receiving active vitamin D analogs, but can also occur later in life [6]. To model these kidney abnormalities, we initially tested *Npt2a*^{-/-} and *Npt2c*^{-/-} mice [22, 24]. Diets with standard calcium and phosphate content (Ca 1.0%, Pi 0.6%) were not reported to induce renal mineralization beyond weaning age in *Npt2a*^{-/-} mice [29] and no mineralization was reported in *Npt2c*^{-/-} mice up to 12 weeks of age [22]. We therefore first tested the effect of a phosphate deficient (Pi 0.02%), high calcium (Ca 2.0%) and high vitamin D₃ (4.5 IU/g) diet intended to maximize hypercalciuria in both mouse models as reported for human individuals with HHRH [6] and mice [30]. However, no renal mineralization was observed at birth, at weaning and up to 12 weeks of life in either mouse strain. Conversely, renal mineralization was seen in *Npt2a*^{-/-} mice when the phosphate content of these diets was raised to 0.3% in CO diet (Fig 1D), while still no such changes were observed in *Npt2c*^{-/-} mice (not shown). Renal mineralization was present




Fig 1. Cortical and medullary renal mineralization. Light micrographs of 10 μm renal sections, prepared from paraffin-embedded kidneys, of mice were fed different diets. WT (a-c), *Npt2a*^{-/-} (d-f), von Kossa&methylene green, 4X; *Npt2a*^{-/-} on CO diet, renal cortex (g) and medulla (h), von Kossa&hematoxylin&eosin, 40X. Transmission electron micrographs showing microspheres in *Npt2a*^{-/-} on CO diet (i), inset with larger magnification shown in (j).

<https://doi.org/10.1371/journal.pone.0176232.g001>

in both intraluminal and interstitial compartments (Fig 1G and 1H), and in addition to staining with the phosphate dye, von Kossa deposits were also positive with the calcium dye alizarin red (not shown). Furthermore, transmission electron images showed concentric calcium phosphate spheres similar to those described by others [29, 31] (Fig 1I and 1J).

Taken together, these findings suggest that dietary phosphate supports the formation of renal mineral deposits, at least under certain conditions, which is contrary to the current belief that oral phosphate supplementation reduces risk for renal calcification in phosphate wasting disorders by normalizing urine calcium excretion.

To further evaluate the dietary conditions influencing the development of renal mineralization, we placed 2-month-old *Npt2a*^{-/-} and wild-type (WT) littermates on three diets containing differing amounts of calcium and phosphate for 10 weeks, while the nutritional vitamin D and magnesium content were kept unchanged: i) HPC diet (High phosphate and calcium diet; 20% lactate, 2% calcium, 1.25% phosphate); ii) HP diet (High phosphate diet; 0.6% calcium, 1.20%

phosphate); or iii) CO diet (Control diet; 0.6% calcium, 0.3% phosphate)(S1 Fig). Lactate in the first diet was shown to increase intestinal absorption of calcium [32]. Size and body weight (BW) of mice in each diet group were indistinguishable and the animals appeared to be thriving well, suggesting that intake of these diets was comparable.

Serum and urine biochemistry of *Npt2a*^{-/-} mice on diets with different calcium and phosphate contents compared to WT

Consistent with previous reports [24, 29] when compared to WT mice serum Pi, plasma PTH and FGF23 were decreased in *Npt2a*^{-/-} mice on the CO diet, while serum 1,25(OH)₂D and urine calcium were increased (Fig 2, Table 1 and S1 Table), albeit only plasma PTH remained significantly decreased after Tukey's correction for multiple comparisons. HP diet increased phosphaturia in *Npt2a*^{-/-} mice and HPC diet increased calciuria in WT and *Npt2a*^{-/-} mice. The urine calcium phosphorus product was increased in *Npt2a*^{-/-} mice on all three diets but not in WT mice, albeit significantly only on HPC diet. Lack of increase of the excretion of phosphate on HPC diet when compared to HP diet may be due to decreased intestinal phosphate absorption as CaHPO₄ salt and suppression of PTH by this diet's calcium content.

Serum BUN levels were in the normal range for all groups, but lower in mutant mice on CO diet and in WT mice on HPC diet. Inulin-clearances measured in the same *Npt2a*^{-/-} mice on HPC diet for 10, 20 and 30 weeks were unaffected (Fig 3A) despite progressive renal mineralization (Fig 3B).

Since urine pH affects renal mineralization, we also determined urine anion gap, which indirectly measures urinary ammonia excretion [33–35]. However, no difference between genotypes and diets was observed. Likewise, no differences were seen for urine excretion oxalate and citrate.

Two-way ANOVA analysis (Table 1) showed a significant effect of diet for S-P, S-BUN, PTH, U-Ca/U-crea, CEI, U-P/U-crea, PEI, U-P*U-Ca/U-crea and U-AG, while there was a significant effect of genotype on S-Ca, S-P, S-BUN, PTH, U-Ca/U-crea, CEI, PEI, U-P*U-Ca/U-crea, and U-Citrate/U-crea. Collectively, these findings suggest that *Npt2a*^{-/-} mice respond differently to dietary phosphate when compared to WT mice.

Addition of calcium to their diet further increased calcium phosphate deposits in *Npt2a*^{-/-}, but not in WT mice

Following 10 weeks on the respective diets the animals were sacrificed, kidneys of *Npt2a*^{-/-} mice fed HPC diet (n = 12) showed 0.58±0.08% calcified area, while *Npt2a*^{-/-} mice fed CO diet (n = 21) showed 0.27±0.18% calcified area (p<0.0001 vs. HPC diet) (Fig 4). Mineralized area was reduced in *Npt2a*^{-/-} mice fed a HP diet (0.23±0.08% calcified area, n = 23) when compared to HPC diet, but was similar when compared to *Npt2a*^{-/-} mice fed CO diet. No mineralization was observed in WT mice on HPC or HP diet, but mineralization was seen in two of ten WT mice on CO diet, albeit less than in *Npt2a*^{-/-} mice on the same diet. Mineralization size was similar on all three diets (calculation see methods, data not shown).

Degree of renal mineralization of *Npt2a*^{-/-} mice directly correlates with blood phosphate and FGF23 levels and urine calcium excretion

A combined univariate linear regression analysis of all *Npt2a*^{-/-} mice showed a significant direct correlation of the urine calcium/urine creatinine ratio (U-Ca/U-cre, CI = 0.49, p = 8.14E-05, n = 59) (Table 2, S1G Fig) and of the calcium excretion index (CEI, CI = 0.39, p = 0.00259, n = 57) (Table 2, S2H Fig) with % calcified area. This analysis also showed a




Fig 2. Biochemical parameters. Serum phosphorus (S-P), serum calcium (S-Ca), serum 1,25(OH)₂-vitamin D (1,25-D), plasma intact PTH (PTH), plasma c-terminal FGF23 (cFGF23), serum blood urea nitrogen (S-BUN), phosphate excretion index (U-Pi/(S-Pi*U-creatinine)) (PEI), calcium excretion index (U-Ca/(S-Ca*U-creatinine)) (CEI), citrate (U-citrate), oxalate (U-oxalate) and anion gap (U-AG). 8 weeks old mice were placed for 10 weeks on special egg-white based diets: HPC diet (High phosphate and calcium diet; 20% lactate, 2% calcium, 1.25% phosphate); HP diet (High phosphate diet; 0.6% calcium, 1.20% phosphate); CO diet (Control diet; 0.6% calcium, 0.3% phosphate); WT: wild type; Npt2a: *Npt2a*^{-/-} mice. The data represent mean±SEM; p-values were obtained by ANOVA and Tukey's test to correct for multiple comparison, selected comparisons shown here, see complete list of p-values in S1 Table.

<https://doi.org/10.1371/journal.pone.0176232.g002>

Table 1. Two-way ANOVA analysis.

	Diet	genotype
S-Ca	0.51	0.04
S-P	0.03	0.01
S-BUN	<0.0001	0.01
PTH	0.05	<0.0001
cFGF23	0.57	0.28
1,25-D	0.20	0.10
U-Ca/U-crea	<0.0001	0.0003
CEI	<0.0001	0.04
U-P/U-crea	<0.0001	0.46
PEI	<0.0001	0.01
U-P*U-Ca/U-crea	0.0002	<0.0001
U-Citrate/U-crea	0.82	0.04
U-oxalate/U-crea	0.12	0.76
U-AG	0.004	0.19

The two genotypes and three diet groups from Fig 2 were subjected to a two-way ANOVA, illustrating that *Npt2a*^{-/-} mice respond differently to their diets. The number of animals included for each diet is shown in S1 Table.

<https://doi.org/10.1371/journal.pone.0176232.t001>

positive correlation of serum phosphate (S-P, CI = 0.39, $p = 0.00402$, $n = 55$) (Table 2, S2B Fig) and plasma FGF23 with % calcified area (cFGF23, CI = 0.36, $p = 0.01036$, $n = 49$) (Table 2, S2E Fig).

Degree of renal mineralization of *Npt2a*^{-/-} mice inversely correlates with urine phosphate excretion and urine anion gap

Univariate linear regression analysis furthermore indicated a significant inverse correlation of the urine phosphate/urine creatinine ratio (U-P/U-cre, CI = -0.27, $p = 0.03855$, $n = 59$) (Table 2, S3A Fig) and of the phosphate excretion index (PEI, CI = -0.37, $p = 0.0084$, $n = 53$) (Table 2, S3B Fig) with % calcified area. Urine anion gap was inversely related to the degree of renal mineral deposits (U-AG, CI = -0.42, $p = 0.01271$, $n = 35$) (Table 2, S3F Fig). No significant association was seen for PTH in Table 2 and S2D Fig although comparison of the means in Fig 2D and S1 Table suggests an inverse relationship between PTH levels and mineralization. Likewise, no significant association was observed for urine citrate/urine creatinine, urine oxalate/urine creatinine or serum 1,25(OH)₂D. Similar trends were seen when evaluating diet groups separately (not shown).

Multivariate linear regression analysis suggests that plasma phosphate, serum FGF23, urine calcium, urine phosphate and anion gap are independent predictors of renal mineral deposits

The observed associations continued to be significant after controlling for gender, or the respective variables independently (Table 2). Urine anion gap remained significant even when controlling for all significant variables simultaneously. A stepwise multivariate linear regression analysis furthermore showed that plasma phosphate was able to explain 58% of the variance in renal mineralization, and both plasma phosphate and CEI combined were able to explain 69% of the variance.




Fig 3. Inulin-clearance is stable in *Npt2a*^{-/-} mice on HPC diet for 10, 20 and 30 weeks despite increased renal mineralization. (A) Inulin-clearance is stable in *Npt2a*^{-/-} mice placed at 8 weeks of age on HPC diet for 10, 20, and 30 weeks, and 175±8, 180±9, and 165±6 ml/min., respectively (mean±SEM) (B) Renal mineralization continues to increase on HPC diet over time from 10 weeks (HPC10) to 30 weeks (HPC30). The data represent individual animals (closed circles) with the means±SEM, p-values shown above the lines of comparisons were calculated by Student's t-test.

<https://doi.org/10.1371/journal.pone.0176232.g003>

Discussion

Oral phosphate supplements are currently thought to reduce risk for renal mineralization in human carriers of *NPT2a* and *NPT2c* mutations. However, as mentioned in the introduction, there is concern that this therapy might contribute to the formation of renal mineralization despite reduced 1,25(OH)₂D levels and thus reduced urinary calcium excretion under certain conditions. Our observation that no mineralization was observed in *Npt2a*^{-/-} and *Npt2c*^{-/-} mice on phosphate deficient diet, while mineralization persisted and/or reappeared in older *Npt2a*^{-/-} mice supplemented with 0.3% phosphorus, further supports this concern.

Tenenhouse et al. [30] found that renal mineralization in *Npt2a*^{-/-} mice resolves at weaning age when the dietary phosphate content was increased from 0.6% to 1%. However, these authors also noticed that mineralization re-appeared when phosphate was further raised to 1.65% despite improved hypercalciuria on this diet. Similarly, we found continued mineralization in older *Npt2a*^{-/-} mice on HP diet containing 1.2% Pi, despite low calciuria, when compared to CO diet and HPC diet (Figs 2 and 4), suggesting that dietary phosphate can be harmful under certain conditions, and that oral phosphate supplementation to treat the bone disease in hypophosphatemic rickets may need to be carefully monitored to not cause renal calcifications.

Renal calcifications were similar when phosphate content was raised from 0.3 to 1.2% in HP diet and only addition of 2% calcium in HPC diet made them worse, suggesting that dietary calcium or the ratio of dietary calcium and phosphorus contributes to mineralization risk.

Renal mineralization was absent in WT mice on HPC and HP diets. These observations suggest that *Npt2a*^{-/-} mice respond differently to dietary phosphate and calcium supplementation when compared to WT.




Fig 4. Renal mineralization is increased in *Npt2a*^{-/-} mice on high phosphate/high calcium diet.

Histomorphometric analysis of renal mineralization (%calcified area = 100*mineralization area/tissue area) in 10 μ m sections of kidneys from mice feed different diets for 10 weeks (see S1 Fig for layout and legend of Table 2 for composition of diets). The data represent individual animals (closed circles) and the mean \pm SEM; p-values were obtained by ANOVA and Tukey's test to correct for multiple comparison.

<https://doi.org/10.1371/journal.pone.0176232.g004>

To better understand the impact of dietary phosphate we considered the possibility that dietary phosphate increases the risk for renal mineralization by raising urine phosphate or the urine calcium x phosphorus product. *Npt2a*^{-/-} mice are predicted to be more susceptible to negative effects of dietary phosphate due to their reduced ability to reclaim phosphate from the urine when compared to WT mice. This hypothesis is supported by the finding that phosphaturia and calcium x phosphorus product (U-Ca*U-P/U-crea) is higher in *Npt2a*^{-/-} mice on HP diet when compared to WT (Fig 2I–2K and S1 Table).

Linear regression analysis of the serum and urine biochemistries of *Npt2a*^{-/-} mice revealed a positive correlation between plasma phosphorus and % calcified area (S2B Fig) and plasma FGF23 and % calcified area (S2E Fig), further supporting the idea that dietary phosphate, by increasing plasma phosphorus and FGF23, can worsen renal calcifications.

It is possible, that FGF23 directly supports renal calcifications in addition to being a marker for oral phosphate load and FGF23-neutralizing antibodies, which have successfully been used in XLH [36] may offer advantages for the risk of renal calcifications when compared to standard therapy with oral phosphate supplements.

However, in light of the positive correlation of plasma phosphate and FGF23 with renal mineralization, we were surprised to find phosphaturia (U-P/U-crea and PEI) inversely related

Table 2. Linear regression analysis.

Parameter	Univariate analysis			Multivariate analysis								
	CC	p-values	n	Sex	S-P	cFGF23	U-Ca/U-crea	CEI	U-P/U-crea	PEI	U-AG	Multiple
S-Ca	0.12	0.4	60	<0.0001	1.0	0.6	0.0001	0.0009	0.03	0.02	0.5	0.3
S-P	0.39	0.004	55	0.006	0.004	0.009	0.1	0.1	0.01	0.1	0.01	1.0
S-BUN	0.07	0.6	59	0.3	0.03	0.7	0.1	0.1	0.68	0.2	0.2	1.0
PTH	0.05	0.7	48	0.0003	0.3	0.3	0.03	0.1	1.0	0.8	0.4	0.4
cFGF23	0.36	0.01	49	0.01	0.004	0.01	0.009	0.003	0.03	0.03	0.2	0.2
1,25-D	-0.01	1.0	46	0.7	0.9	0.7	0.7	0.8	0.5	0.5	0.2	0.7
U-Ca/U-crea	0.49	<0.0001	59	<0.0001	0.004	0.001	<0.0001	0.009	0.0008	0.002	0.002	0.8
CEI	0.39	0.003	57	0.0002	0.03	0.01	0.4	0.002	0.01	0.03	0.008	0.4
U-P/U-crea	-0.27	0.04	59	0.04	0.04	0.1	0.4	0.23	0.04	0.81	0.6	0.4
PEI	-0.37	0.008	53	0.01	0.2	0.003	0.1	0.08	0.2	0.008	0.3	0.4
U-P*U-Ca/U-crea	0.23	0.09	57	0.2	0.7	0.2	0.1	0.7	0.02	0.09	0.01	0.02
U-Citrate/U-crea	0.15	0.4	32	0.4	0.5	0.5	0.2	0.2	0.3	0.3	0.94	0.6
U-oxalate/U-crea	0.20	0.3	33	0.4	0.34	0.6	0.2	0.07	0.09	0.1	0.3	0.1
U-AG	-0.42	0.01	35	0.02	0.008	0.1	0.06	0.04	0.03	0.008	0.01	0.001

Following univariate linear regression analysis of all experimental *Npt2a*^{-/-} mice analysis of covariance (multivariate analysis) was used to control for influence of gender, variables separately as indicated in the column header or to control for multiple variables (S-P, cFGF23, U-Ca/U-crea, CEI, U-P/U-crea, PEI, U-AG). The number of animals included for each diet is shown in S1 Table.

<https://doi.org/10.1371/journal.pone.0176232.t002>

to renal mineralization (Table 2 and S3A and S3B Fig). Furthermore, renal mineralization was present in both intraluminal and interstitial compartments (Fig 1G and 1H), while loss of *Npt2a* by modifying reabsorption of phosphate from the urine would be predicted to cause nephrocalcinosis rather than nephrolithiasis in these mice [17, 18]. Thus additional factors may determine risk for renal mineralization in addition to increased intraluminal phosphate in *Npt2a*^{-/-} mice on HP diet, for example reduced osteopontin excretion as previously reported by us [21], or interstitial levels of phosphate.

We also evaluated for changes in other stone risk factors [17, 18], but no differences were observed in urine citrate and oxalic acid excretion when comparing WT and *Npt2a*^{-/-} mice (Fig 2L and 2M, S1 Table), or when using linear regression analysis of the *Npt2a*^{-/-} cohort (Table 2, S3F and S3G Fig). However, urine anion gap, which is an indirect measure of renal ammonia excretion, was found to be inversely correlated with the degree of renal mineralization (Table 2, S3H Fig). High urine anion gap is characteristically seen with impaired urine ammonia excretion in renal tubular acidosis type 1, while low or negative urine anion gap can occur in the context of proximal tubular bicarbonate loss in renal tubular acidosis type 2 [33–35]. The latter would be consistent with reports of Fanconi-type syndrome due to loss-of-function mutations in *NPT2a* in human individuals [2], and suggests that urine pH could be an additional risk factor for stone formation in *Npt2a*^{-/-} mice.

The observed inverse relation of urine anion gap with the degree of renal mineralization persisted when controlled for P-P, cFGF23, U-Ca/U-crea, CEI, U-P/U-crea, PEI, U-AG separately or in combination (Table 2), and likewise when *Npt2a*^{-/-} mice were analyzed for each diet separately (not shown). Taken together our findings suggest that proximal tubular function beyond phosphate transport may be impaired which could contribute to the formation of renal mineralization in *Npt2a*^{-/-} mice.

A limitation of this study is that *Npt2a*^{-/-} mice exhibit a milder biochemical phenotype than that seen in most humans with loss-of-function mutations in *NPT2a*. Renal mineralization also resolves after weaning [29, 31] in this mouse model and composition of mineral deposits

may differ between mice and humans who carry *NPT2a* mutations. However, our findings that renal stones and nephrocalcinosis persist and/or reappear in older *Npt2a*^{-/-} mice under certain conditions, and earlier reports and our own TEM studies show that these mineral deposits have a composition similar to Randall's plaques ([31] and Fig 1I and 1J) argue that despite these species-related differences, important insights can be gained into the underlying pathophysiology of nephrolithiasis and nephrocalcinosis in this mouse model. Metabolic cage studies are needed to formally assure similar intake of the different diets, however similar weight gain of all three cohorts on CO, HP and HPC diets is reassuring. Direct determination of urine pH and bicarbonate excretion requires dissection of bladders from a new cohort of mice and will be subject of future studies to confirm indirect evidence obtained from urine anion gap measurements presented here. Lastly, a time course of renal mineralization is necessary to determine whether neonatal and weaning-age mineralization, which presumably formed during relatively high calcium and phosphate intake with the breast milk, did not resolve when animals are maintained on HP diet after weaning. Or whether new mineralization developed on HP diet, as suggested by our observation that renal mineralization continues to increase in mice between 10 and 30 weeks on HPC diet (Fig 3B).

In summary, we show here that *Npt2a*^{-/-} mice respond differently to dietary phosphate when compared to WT mice and that the degree of renal mineralization positively correlates with serum phosphate, plasma FGF23, and urinary calcium excretion, while it inversely correlates with urine phosphate and urine anion gap. Our observations in *Npt2a*^{-/-} mice suggest presence of risk factors for renal mineralization in addition to hypercalciuria, and if confirmed in humans our findings may be relevant for the optimization of existing and for the development of novel therapies to prevent nephrolithiasis and nephrocalcinosis in human carriers of *NPT2a* and *NPT2c* mutations.

Supporting information

S1 Fig. Experimental design. At 8 weeks of age they were randomized to special diets for 10 to 30 weeks: HPC (high phosphate and high calcium diet, 20% Lactose, 2.0% Ca, 1.25% Pi; HP (high phosphate diet, 0.6% Ca, 1.2% Pi and CO (control diet, 0.6%Ca, 0.3% Pi). Mice were sacrificed at after 10 weeks or 30 weeks on these diets.
(TIF)

S2 Fig. Urinary calcium excretion and plasma FGF23 levels are positively correlated with renal mineralization in a combined univariate linear regression analysis *Npt2a*^{-/-} mice fed different diets. All experimental *Npt2a*^{-/-} mice from S1 Table (n = 56) were evaluated using linear regression analysis to determine the association of renal mineralization with serum calcium (S-Ca, A), serum phosphorus (S-P, B), serum BUN (S-BUN, C), plasma intact PTH (PTH, D), plasma c-terminal FGF23 (cFGF23, E), serum 1,25(OH)₂-vitamin D (1,25(OH)₂-D, F), the ratios of urine calcium/urine creatinine (U-Ca/U-crea, G), and urine calcium excretion index (CEI, H). Data points represent values of individual animals. Results of the linear regression analysis are shown as solid line with 95% confidence interval (stippled lines), for correlation coefficients and Pearson's p-values see Table 2.
(TIFF)

S3 Fig. Urinary phosphate excretion and anion gap are negatively correlated with renal mineralization in a combined univariate linear regression analysis *Npt2a*^{-/-} mice fed different diets. All experimental *Npt2a*^{-/-} mice from S1 Table (n = 56) were evaluated using linear regression analysis to determine the association of renal mineralization with the ratios of urine phosphorus/urine creatinine (U-P/U-crea, A), urine phosphate excretion index (PEI, B), urine

calcium*phosphorus/urine creatinine (U-Ca*U-P/U-crea, **C**), urine citrate/urine creatinine (U-citrate/U-crea, **D**), urine oxalate/urine creatinine (U-oxalate/U-crea, **E**), urine anion gap (U-AG, **F**). Data points represent values of individual animals. Results of the linear regression analysis are shown as solid line with 95% confidence interval (stippled lines), for correlation coefficients and Pearson's p-values see [Table 2](#).

(TIFF)

S1 Table. Biochemical parameters. Serum phosphorus (S-P), serum calcium (S-Ca), serum 1,25(OH)₂-vitamin D (1,25-D), plasma intact PTH (iPTH), plasma c-terminal FGF23 (cFGF23), serum blood urea nitrogen (S-BUN), phosphate excretion index (U-Pi/(S-Pi*U-creatinine)(PEI), calcium excretion index (U-Ca/(S-Ca*U-creatinine) (CEI), citrate (U-citrate), oxalate (U-oxalate) and anion gap (U-AG). All diets are egg-white based: HPC diet (High phosphate and calcium diet; 20% lactate, 2% calcium, 1.25% phosphate); HP diet (High phosphate diet; 0.6% calcium, 1.20% phosphate); CO diet (Control diet; 0.6% calcium, 0.3% phosphate); WT, wild type; The data represent mean±SEM; p-values were obtained by ANOVA and Tukey's test to correct for multiple comparison.

(XLSX)

Acknowledgments

This work was supported by National Institutes of Health Grants R01-DK46718-20 and P01-DK11794, project IV (to H.J.), National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Grant 5K08-DK078361 (to C.B.), Center for Skeletal Research Core NIH P30 AR066261 (to M.D.), Young Investigator Awards by the National Kidney Foundation, and the American Society for Clinical Investigation (to C.B.), National Natural Science Foundation of China grant 81271713 (to C.Z.) and the Scientific research fund of Anhui Medical University 2011xkj074 (to Y.L.). We are grateful to the Yale Mouse Metabolic Phenotyping Center NIH U24 DK-059635 and the Yale O'Brien Center Renal Physiology Core NIH P30DK079310 for help with biochemical analysis, the Yale Dept. of Orthopaedics Histology and Histomorphometry Laboratory for help with histological and the Yale Center for Cellular and Molecular Imaging (YCCMI) for electron microscopic analysis and Xiaoquin Yu, Ph.D., at the Yale School of Medicine Dept. Biostatistics for help with statistical analysis.

Author Contributions

Conceptualization: CB HJ.

Data curation: YL AC CB.

Formal analysis: AC CB.

Funding acquisition: YL CZ CB HJ MD.

Investigation: YL CZ DC JP.

Methodology: CB.

Project administration: CB.

Resources: MD JG.

Software: AC.

Supervision: CB.

Validation: CB.

Visualization: CB.

Writing – original draft: YL CB.

Writing – review & editing: CB HJ.

References

1. Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. *N Engl J Med*. 2002; 347(13):983–91. <https://doi.org/10.1056/NEJMoa020028> PMID: 12324554
2. Magen D, Berger L, Coady MJ, Ilivitzki A, Militianu D, Tieder M, et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. *N Engl J Med*. 2010; 362(12):1102–9. <https://doi.org/10.1056/NEJMoa0905647> PMID: 20335586
3. Schlingmann KP, Ruminska J, Kaufmann M, Dursun I, Patti M, Kranz B, et al. Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia. *J Am Soc Nephrol*. 2015. Epub 2015/06/07.
4. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, et al. Hereditary Hypophosphatemic Rickets with Hypercalciuria Is Caused by Mutations in the Sodium-Phosphate Cotransporter Gene SLC34A3. *Am J Hum Genet*. 2006; 78(2):193–201. <https://doi.org/10.1086/499410> PMID: 16358215
5. Bergwitz C, Roslin NM, Tieder M, Loredó-Osti JC, Bastepe M, Abu-Zahra H, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. *Am J Hum Genet*. 2006; 78(2):179–92. Epub 2005/12/17. PubMed Central PMCID: PMC1380228. <https://doi.org/10.1086/499409> PMID: 16358214
6. Tieder M, Arie R, Bab I, Maor J, Liberman UA. A new kindred with hereditary hypophosphatemic rickets with hypercalciuria: implications for correct diagnosis and treatment. *Nephron*. 1992; 62(2):176–81. PMID: 1436310
7. Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, et al. Hereditary hypophosphatemic rickets with hypercalciuria. *N Engl J Med*. 1985; 312(10):611–7. <https://doi.org/10.1056/NEJM198503073121003> PMID: 2983203
8. Arcidiacono T, Mingione A, Macrina L, Pivari F, Soldati L, Vezzoli G. Idiopathic calcium nephrolithiasis: a review of pathogenic mechanisms in the light of genetic studies. *Am J Nephrol*. 2014; 40(6):499–506. Epub 2014/12/17. <https://doi.org/10.1159/000369833> PMID: 25504362
9. Boger CA, Gorski M, Li M, Hoffmann MM, Huang C, Yang Q, et al. Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. *PLoS Genet*. 2011; 7(9):e1002292. Epub 2011/10/08. PubMed Central PMCID: PMC3183079. <https://doi.org/10.1371/journal.pgen.1002292> PMID: 21980298
10. Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nat Commun*. 2016; 7:10023. Epub 2016/02/03. PubMed Central PMCID: PMC4735748. <https://doi.org/10.1038/ncomms10023> PMID: 26831199
11. Dinour D, Davidovits M, Ganon L, Ruminska J, Forster IC, Hernando N, et al. Loss of function of NaPiIIa causes nephrocalcinosis and possibly kidney insufficiency. *Pediatr Nephrol*. 2016; 31(12):2289–97. Epub 2016/07/06. <https://doi.org/10.1007/s00467-016-3443-0> PMID: 27378183
12. Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. *J Am Soc Nephrol*. 2015; 26(3):543–51. Epub 2014/10/10. PubMed Central PMCID: PMC4341487. <https://doi.org/10.1681/ASN.2014040388> PMID: 25296721
13. Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ. Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. *J Pediatr*. 1992; 120(6):899–905. Epub 1992/06/01. PMID: 1317418
14. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. *J Bone Miner Res*. 2011; 26(7):1381–8. Epub 2011/05/04. PubMed Central PMCID: PMC3157040. <https://doi.org/10.1002/jbmr.340> PMID: 21538511
15. Gonlusen G, Akgun H, Ertan A, Olivero J, Truong LD. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. *Arch Pathol*

- Lab Med. 2006; 130(1):101–6. Epub 2006/01/05. [https://doi.org/10.1043/1543-2165\(2006\)130\[101:RFANAW\]2.0.CO;2](https://doi.org/10.1043/1543-2165(2006)130[101:RFANAW]2.0.CO;2) PMID: 16390223
16. Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, et al. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. *J Am Soc Nephrol*. 2014; 25(10):2366–75. Epub 2014/04/05. PubMed Central PMCID: PMC4178443. <https://doi.org/10.1681/ASN.2013101085> PMID: 24700880
17. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. *Clin Sci (Lond)*. 2004; 106(6):549–61. Epub 2004/03/19.
18. Worcester EM, Coe FL. Nephrolithiasis. *Prim Care*. 2008; 35(2):369–91, vii. Epub 2008/05/20. PubMed Central PMCID: PMC2518455. <https://doi.org/10.1016/j.pop.2008.01.005> PMID: 18486720
19. Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. *Calcif Tissue Int*. 2013; 93(4):348–54. Epub 2013/01/22. <https://doi.org/10.1007/s00223-013-9698-6> PMID: 23334303
20. Li Q, Chou DW, Price TP, Sundberg JP, Uitto J. Genetic modulation of nephrocalcinosis in mouse models of ectopic mineralization: the *Abcc6(tm1Jfk)* and *Enpp1(asj)* mutant mice. *Lab Invest*. 2014; 94(6):623–32. Epub 2014/04/16. PubMed Central PMCID: PMC4039617. <https://doi.org/10.1038/labinvest.2014.52> PMID: 24732453
21. Caballero D, Li Y, Ponsetto J, Zhu C, Bergwitz C. Impaired urinary osteopontin excretion in *Npt2a*^{-/-} mice. *Am J Physiol Renal Physiol*. 2016;ajprenal.00367.2016. Epub 2016/10/28.
22. Segawa H, Onitsuka A, Furutani J, Kaneko I, Aranami F, Matsumoto N, et al. *Npt2a* and *Npt2c* in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. *Am J Physiol Renal Physiol*. 2009; 297(3):F671–8. <https://doi.org/10.1152/ajprenal.00156.2009> PMID: 19570882
23. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. *J Bone Miner Res*. 1998; 13(7):1101–11. Epub 1998/07/14. <https://doi.org/10.1359/jbmr.1998.13.7.1101> PMID: 9661074
24. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of *Npt2* in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. *Proc Natl Acad Sci U S A*. 1998; 95(9):5372–7. PMID: 9560283
25. Albright RA, Stabach P, Cao W, Kavanagh D, Mullen I, Braddock AA, et al. ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. *Nat Commun*. 2015; 6:10006. Epub 2015/12/02. PubMed Central PMCID: PMC4686714. <https://doi.org/10.1038/ncomms10006> PMID: 26624227
26. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. *J Clin Endocrinol Metab*. 2006; 91(6):2055–61. Epub 2006/03/23. <https://doi.org/10.1210/jc.2005-2105> PMID: 16551733
27. Maeda A, Okazaki M, Baron DM, Dean T, Khatri A, Mahon M, et al. Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. *Proc Natl Acad Sci U S A*. 2013; 110(15):5864–9. Epub 2013/03/28. PubMed Central PMCID: PMC3625299. <https://doi.org/10.1073/pnas.1301674110> PMID: 23533279
28. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. *Am J Physiol Renal Physiol*. 2004; 286(3):F590–6. Epub 2003/11/06. <https://doi.org/10.1152/ajprenal.00324.2003> PMID: 14600035
29. Chau H, El-Maadawy S, McKee MD, Tenenhouse HS. Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene *Npt2*. *J Bone Miner Res*. 2003; 18(4):644–57. Epub 2003/04/04. <https://doi.org/10.1359/jbmr.2003.18.4.644> PMID: 12674325
30. Tenenhouse HS, Gauthier C, Chau H, St-Arnaud R. 1 α -Hydroxylase gene ablation and Pi supplementation inhibit renal calcification in mice homozygous for the disrupted *Npt2a* gene. *Am J Physiol Renal Physiol*. 2004; 286(4):F675–81. <https://doi.org/10.1152/ajprenal.00362.2003> PMID: 14656762
31. Khan SR, Canales BK. Ultrastructural investigation of crystal deposits in *Npt2a* knockout mice: are they similar to human Randall's plaques? *J Urol*. 2011; 186(3):1107–13. Epub 2011/07/26. PubMed Central PMCID: PMC3625924. <https://doi.org/10.1016/j.juro.2011.04.109> PMID: 21784483
32. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. *Endocrinology*. 1998; 139(10):4391–6.
33. Reddy P, Mooradian AD. Clinical utility of anion gap in deciphering acid-base disorders. *Int J Clin Pract*. 2009; 63(10):1516–25. Epub 2009/09/23. <https://doi.org/10.1111/j.1742-1241.2009.02000.x> PMID: 19769708

34. Sharma S, Gupta A, Saxena S. Comprehensive clinical approach to renal tubular acidosis. Clin Exp Nephrol. 2015; 19(4):556–61. Epub 2015/05/09. <https://doi.org/10.1007/s10157-015-1119-x> PMID: [25951806](#)
35. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002; 13(8):2160–70. Epub 2002/07/26. PMID: [12138150](#)
36. Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014; 124(4):1587–97. Epub 2014/02/27. PubMed Central PMCID: PMC3973088. <https://doi.org/10.1172/JCI72829> PMID: [24569459](#)